Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Gynecol Pathol ; 31(2): 192-194, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22317879

ABSTRACT

Neurofibromatosis type 1 is an autosomal dominant disorder characterized by the presence of cutaneous and subcutaneous neurofibromas as well as deep-seated plexiform neurofibromas. Although unusual, these lesions have been described in the gynecologic tract, including the cervix; however, when arising in this location, they are commonly asymptomatic or present with lower abdominal pain. Cervical neurofibromas presenting as cervical stenosis have not been described. Awareness by both the clinician and the pathologist of a patient's history is of great help when dealing with a specimen of a patient with neurofibromatosis type 1.


Subject(s)
Neurofibromatosis 1/pathology , Uterine Cervical Neoplasms/pathology , Constriction, Pathologic/pathology , Female , Humans , Middle Aged
2.
Toxicol Sci ; 105(1): 221-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18539914

ABSTRACT

These studies describe the effect of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide (AR-M100390), a delta-opioid agonist, on the pancreas and its mechanisms for pancreatic toxicity. Rats were treated with 5, 100, and 600 micromol/kg of AR-M100390 for 3 and/or 7 days; another group of rats treated with 600 micromol/kg of compound were allowed to recover for 14 days. AR-M100390 (600 micromol/kg) caused vacuolation in the beta-cell of the rat pancreas that was associated with depletion of insulin and hyperglycemia after 7 days of dosing. The loss of insulin by AR-M100390 was due to specific inhibition of rat insulin2 mRNA transcription in vivo. Insulin depletion and hyperglycemia were reversible. The effects of AR-M100390 in rats were reproduced in the rat pancreatic beta-cell line RINm5F, where it inhibited intracellular insulin content and secretion without affecting cell survival. Loss of insulin in vitro was also a result of specific inhibition of insulin2 mRNA transcription and was reversible. Pretreatment of cells with the delta-opioid antagonist naltrindole or pertussis toxin did not reverse loss of insulin in AR-M100390-treated cells suggesting that the effects were not mediated by the delta-opioid receptor. AR-M100390 inhibited KCl-mediated calcium mobilization in RINm5F cells, suggesting that L-type calcium channels found in these cells and in pancreatic beta-cells may partially play a role in the inhibition of insulin secretion by this compound. In summary, the in vitro and in vivo studies suggest that inhibition of insulin by AR-M100390 is due to a combination of inhibition of insulin synthesis and/or release.


Subject(s)
Benzamides/toxicity , Insulin/metabolism , Pancreas/drug effects , Piperidines/toxicity , Receptors, Opioid, delta/agonists , Animals , Blood Glucose/analysis , Calcium/metabolism , Calcium Channels, L-Type/physiology , Cells, Cultured , Cyclizine/toxicity , Dose-Response Relationship, Drug , Insulin/genetics , Pancreas/metabolism , RNA, Messenger/analysis , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...